Company Encyclopedia
View More
name
InflaRx NV
IFRX.US
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS.
1.946 T
IFRX.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking288/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-72.49%E
    • Profit Margin-63818.90%E
    • Gross Margin98.60%A
  • Growth ScoreE
    • Revenue YoY-61.87%E
    • Net Profit YoY27.93%B
    • Total Assets YoY-14.12%E
    • Net Assets YoY-27.01%E
  • Cash ScoreD
    • Cash Flow Margin-0.16%D
    • OCF YoY-61.87%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreB
    • Gearing Ratio30.37%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    InflaRx (NASDAQ:IFRX) Announces Quarterly Earnings Results, Hits Estimates

    InflaRx (NASDAQ: IFRX) announced its quarterly earnings, reporting an EPS of ($0.16), meeting analysts' expectations. The company also reported revenue of $0.03 million, aligning with forecasts. The stock traded at $1.68, with a market cap of $112.78 million. Analysts have mixed ratings, with a consensus of 'Moderate Buy' and an average price target of $8.60. InflaRx is a clinical-stage biopharmaceutical company focusing on C5a technology for inflammatory diseases.

    Market Beat·
    US
    IFRX
    +7.84%
    Market Beat·
    US
    IFRX
    +7.84%

    Cautious Hold Rating for InflaRx’s INF904 Amid Uncertainties in Trial Results

    LifeSci Capital analyst Sam Slutsky has maintained a Hold rating on InflaRx’s IFRX stock due to uncertainties in trial results for INF904. The Phase 2a study showed some promising trends in hidradenitis suppurativa but had limitations, including a small sample size and lack of a placebo arm. For chronic spontaneous urticaria, the data did not indicate strong efficacy. The company plans to seek a partnership for further development, leading to a cautious outlook. Another report also reiterated a Hold rating with a $1.50 price target.

    Tip Ranks·
    US
    IFRX
    +7.84%
    Tip Ranks·
    US
    IFRX
    +7.84%

    InflaRx shares are trading higher after Guggenheim raised its price target on the stock from $10 to $22 while maintaining a Buy rating.

    benzinga_article·
    US
    IFRX
    +7.84%
    benzinga_article·
    US
    IFRX
    +7.84%

    InflaRx Says Phase 2a Data Support Further Development of INF904 in 2 Skin Conditions

    InflaRx (IFRX) announced positive results from a Phase 2a study of INF904 for hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU), showing improvements in clinical endpoints. The company plans to proceed to a Phase 2b trial in 2026 after completing a four-week post-treatment observation. Following the announcement, shares of InflaRx rose over 26% in trading.

    fidelity·
    US
    IFRX
    +7.84%
    fidelity·
    US
    IFRX
    +7.84%

    InflaRx Reports Q3 2025 Financial Results Highlighting Operational Challenges

    InflaRx N.V. reported its Q3 2025 financial results, revealing revenues of €123,819 for the quarter and €166,212 for the nine months ended September 30, 2025. The company faced a gross loss of €2,345,945, highlighting operational challenges, particularly in research and development. Analysts rate IFRX stock as a Hold with a $1.00 price target, while TipRanks’ AI Analyst considers it Neutral due to ongoing losses and cash flow issues. InflaRx specializes in treatments for inflammatory diseases and is based in Germany and the Netherlands.

    Tip Ranks·
    US
    IFRX
    +7.84%
    Tip Ranks·
    US
    IFRX
    +7.84%
    © 2025 Longbridge｜Disclaimer